Biogen Inc. and partner Eisai Co. Ltd. are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of the company’s value.
Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.
Here is a look at BioSpace’s top 10 stories of 2018.
U.S. drugmaker Eli Lilly and Co. and AC Immune SA agreed to jointly develop the Swiss biotech’s potential treatment for Alzheimer’s disease.
Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.
Researchers at the University of Texas Health Science Center at San Antonio found a type of cellular stress in Alzheimer’s disease for the first time that is involved in cancer and aging.
The U.S. FDA declined to approve Pain Therapeutics Inc.’s abuse-deterrent opioid treatment Remoxy for the fourth time.
Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.
Biogen Inc. reported far better-than-expected second-quarter 2018 profit, driven by strong demand of the company’s Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.
Eisai Co. Ltd. and Biogen Inc. will move forward with late-stage clinical trials of their Alzheimer’s disease drug BAN2401, and the companies are working with regulators to design the next studies and gain expedited review as a breakthrough therapy.